Drug carrier systems for solubility enhancement of BCS class II drugs: A critical review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 3, 2013, Pages 217-256

  Kumar, Sumit ^a   Bhargava, Deepak ^a   Thakkar, Arti ^a   Arora, Saahil ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

BCS class II; Colloidal liquid crystalline structures; Cyclodextrin; Nanonization; Solid dispersions; Solubility

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTHELMINTIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CURCUMIN; CYCLODEXTRIN; CYCLOSPORIN; CYCLOSPORIN A; DRUG CARRIER; ESTRADIOL; FENOFIBRATE; GRISEOFULVIN; ITRACONAZOLE; LIPOSOME; METFORMIN; METOPROLOL; NANOCRYSTAL; NEUROLEPTIC AGENT; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PRODRUG; PROPRANOLOL; RAPAMYCIN; SOLID LIPID NANOPARTICLE; THEOPHYLLINE; UNINDEXED DRUG;

ARTICLE; COLLOID; COMPLEX FORMATION; CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GRANULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; EMULSION; LIPOPHILICITY; MICELLE; NANOEMULSION; PARTICLE SIZE; PH; SOLUBILIZATION; TABLET COMPRESSION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 84876766388     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005964     Document Type: Article

References (252)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3-26.
2. Giliyar C, Fikstad DT, Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly water-soluble drugs. Drug Deliv Technol. 2006; 6: 57-63.
3. Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur. J Pharm Biopharm. 2007;65:26-38.
4. Chawdhary KPR, Vijayasrinivas S. Biopharmaceutical classification system. Indian Pharmacist. 2007;2:7-10.
5. Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003;26:322-6.
6. Hayden FG, Jennings L, Robson R, Schiff G, Jackson H. Oral oseltamivir in human experimental influenza B infection. Antivir Ther. 2000;5:205-13.
7. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993;24:195-202.
8. Milano G, Ferrero JM, Francois E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004;91: 613-7.
9. Yoshikawa M, Nishiyama S, Takaiti O. Metabolism of dopamine prodrug, docarpamine. Hypertens Res. 1995;18:S211-3.
10. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
11. Yu LX, Amidon GL, Polli GL, Zhao H, Mehta MU, Conner DL, Shah VP, Lesko LJ, Chen ML, Lee VHL, Hussain AS. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19:921-5.
12. FDA, 2000. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed 13 April 2011.
13. Seema R, Ankur R, Marwaha RK, Nanda A. BCS: a strategic tool for classifying drug substance. Int Res J Pharm. 2011;2(7):53-9.
14. Cook J, Addicks W, Wu YH. Application of the biopharmaceutical classification system in clinical drug development-an industrial view. AAPS. 2008;10:306-10.
15. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
16. Blagden, N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617-630.
17. Xia D, Cui F, Piao H, Cun D, Jiang Y, Ouyang M, Quan P. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res. 2010;27:1965-76.
18. He CX, He ZG, Gao JQ. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin on Drug Deliv. 2010a; 7:445-60.
19. Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B, Yamada S. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010b;99:1871-81.
20. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm and Biopharm. 2000;50:3-12.
21. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46:75-87.
22. Efentakis M, Dressman JB. Gastric juice as a dissolution medium: surface tension and pH. Eur J Drug Metab Pharmacokinet.1998;23:97-102.
23. Macheras P, Koupparis M, Apostelelli E. Dissolution for controlled release theophylline formulations in milk. Int J Pharm. 2007;36:73-9.
24. Dressaman JB, Lennernas H, Oral drug absorption prediction and assessment. New York: Marcel Dekker. 2000. p. 159-73.
25. DE. Small intestinal pH and buffer capacity: implications for dissolution of ionizable compounds. Doctoral dissertation, the University of Michigan, Ann Arbor, MI. 1994.
26. Galia E, Nicolaides E, Lobenberg RD, Dressman JB. Evaluation of various dissolution media predicting in vivo performance of class I and Class II drugs. Pharm Res. 1998; 15:698-705.
27. USP-27, NF-22nd edition, United State Pharmacopeial convention, Inc., Rockville, MD. 2004; 2303-2312.
28. Dressaman JB, Lennernas H. Oral drug absorption prediction and assessment. New York: Marcel Dekker. 2000. pp. 174-5, 183-95.
29. FIP guidelines for dissolution testing of solid oral products. Pharm Ind. 1997;59:760-5.
30. Oberle RX, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm.1987;15:529-44.
31. Yu LX. An integrated absorption model for determining dissolution, permeability, and solubility limited absorption. Pharm Res. 1999;16:1884-8.
32. Stella VJ. Prodrugs as therapeutics. Expert Opin Ther Patents 2004; 14(3):277-80.
33. Testa B. Prodrug research: futile or fertile? Biochem Pharmacol. 2004; 68:2097-106.
34. Safad M, Oliyai R, Stella VJ. Phosphoryloxymethyl carbamates and carbonatesnovel watersoluble prodrugs for amines and hindered alcohols. Pharm Res. 1993;10:1350-5.
35. Majumdar S, Sloan KB. Synthesis, hydrolyses and dermal delivery of nalkylnalkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs. Bioorg Med Chem Lett. 2006;16:3590-4.
36. Peyrottes S, Egron D, Lefebvre I, Gosselin G, Imbach JL, Perigaud C. SATE pronucleotide approaches: an overview. Mini Rev Med Chem. 2004;4:395-408.
37. Fozard JR. BP294 Ste Civile Bioprojet. Curr. Opin. Investig. Drugs 2000;1:869.
38. Simplicio AL, Clancy JM, Gilmer JF. beta Aminoketones as prodrugs with pH-controlled activation. Int J Pharm. 2007;336:208-214.
39. Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab. 2003;4: 461-85.
40. Potter PM, Wadkins RM. Carboxylesterases detoxifying enzymes and targets for drug therapy. Curr Med Chem. 2006;13:104-554.
41. Heimbach T, Fleisher D, Kaddoumi A. Overcoming poor aqueous solubility of drugs for oral delivery. In Stella V, Borchardt RT, Hageman M, Oliyai R, Maag H, Tilley H, editors. Prodrugs: challenges and rewards. New York: AAPS Press/Springer. 2007. p. 155-212.
42. Heimbach T, Oh DM, Li LY, Rodriguez Hornedo N, Garcia G, Fleisher D. Enzymemediated precipitation of parent drugs from their phosphate prodrugs. Int J Pharm. 2003;261:81-92.
43. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci. 2004;21:316.
44. Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as prodrugs of amidines. Drug Metab Rev. 2002;34:565-79.
45. Kumpulainen H, Mahonen N, Laitinen ML, Jaurakkajarvi M, Raunio H, Juvonen RO, Vepsalainen J, Jarvinen T, Rautio J. Evaluation of hydroxyimine as cytochrome P450selective prodrug structure. J Med Chem. 2006;49:1207-11.
46. Stella VJ, NtiAddae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007;59(7):677-694.
47. Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet. 1998;34:163-72.
48. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45:137-68.
49. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001;61:263-83.
50. O'Malley P. Bird flu pandemic and Tamiflu: implications for the clinical nurse specialist. Clin Nurse Spec. 2006;20:657.
51. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. Antiinfluenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006;319:1477-84.
52. Sweetana S, Akers MJ. Solubility principles and practices for parenteral dosage form development, PDA. J Pharm Sci Tech.1996;50:330-42.
53. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;34:34-9.
54. Serajuddin ATM, Pudipeddi M. Salt-selection strategies, in: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection and use. Weinheim: Wiley-VCH; 2002. p.135-60.
55. Ward SC, Hursthouse MB, Woodsand DC, Lewis SM. Systematic study into the salt formation of functionalised organic substrates. School of Chemistry, University of Southampton, Southampton, SO17 1BJ, UK.
56. Childs SL, Stahly GP, Park A. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Molec Pharma. 2007;4:323-38.
57. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59:603-16.
58. Li S, Wong S, Sethia S, Almoazen H, Joshi YM, Serajuddin AT. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 2005;22:628-35.
59. Guzman HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686-702.
60. Aakeroy CB, Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility. Cryst Eng Comm. 2005;7:439-48.
61. Lu J, Rohani S. Preparation and characterization of theophylline-nicotinamide omogeniza. Org Process Res Dev. 2009;13:1269-75.
62. Blagden N, Berry DJ, Parkin A, Javed H, Ibrahim A, Gavan PT, De Matos LL, Seaton CC. Current directions in co-crystal growth. New J Chem. 2008;32:1659-72.
63. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9:2950-67.
64. Reutzel-Edens SM, Newman AW. Physical characterization of hygroscopicity in pharmaceutical solids. In: Hilfiker R, editor. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH Verlag GmbH; 2006. p. 235-58.
65. Aakeroy CB, Forbes S, Desper J. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc. 2009;131:17048-9.
66. Aakeroy CB, Salmon DJ, Smith MM, Desper J. Cyanophenyloximes: reliableand versatile tools for hydrogen-bond directed supramolecular synthesis of cocrystals. Cryst Growth Des. 2006;6:1033-42.
67. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of activepharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617-30.
68. Oswald IDH, Allan DR, McGregor PA, Motherwell WDS, Parsons S, Pulham CR. The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors. Acta Crystallogr Sect. B. 2002;58:1057-66.
69. Good DJ, Rodriguez-Hornedo N. Cocrystal eutectic constants and prediction of solubility behavior. Cryst Growth Des. 2010;10:1028-32.
70. Shinde A. Solublization of poorly water soluble drugs. Pharminfo.net. 2007;5.
71. Patil SK, Wagh KS, Parik VB, Akarte AM, Baviskar DT. Strategies for solubility for solubility enhancement of poorly soluble drugs. 2011;8(2): Article-013.
72. Millard JW, Alvarez-Núñez FA, Yalkowsky FH. Solubilization by cosolvents: establishing useful constants for the log-linear model. Int. J. Pharm. 2002;245(1-2):153-66.
73. Pareek V, Tambe SR, Bhalerao SB. Role of different hydrotropic agents in spectrophotometric andchromatographic estimation of cefixime. Int J Pharma and Bio Sci. 2010;1(3):1-10.
74. Saleh am el-khordagui lk. Hydrotropic agents: a new definition. Int J Pharm. 1985;24:231-8.
75. Lee J, Lee SC, Acharya G, Chang CJ, Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res. 2003;20:1022-30.
76. Suzuki H, Sunada H. Mechanistic studies on hydrotropic solubilization of nifedipine in nicotinamide solution. Chem Pharm Bull. 1998;46:125-30.
77. Poochikian GD, Gradock JC. Enhanced chartreusin solubility by hydroxybenzoate hydrotropy. J Pharm Sci. 1979;68:728-32.
78. Kim JY, Kim S, Papp M, Park K, Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. Wiley Interscience. DOI 10.1002/jps.22241.
79. Zhang GGZ, Gu C, Zell MT, Burkhardt RT, Munson EJ, Grant DJW. Crystallization and transitions of sulfamerazine polymorphs. J J Pharm Sci. 2002;91:1089-100.
80. Verma AR, Krishna P. Polymorphism and Polytypism in Crystals. New York: Wiley; 1966. p. 15-30.
81. Chan HK, Doelker E. Polymorphic transformation of some drugs under compression. Drug Dev Ind Pharm.1985;11:315-32.
82. Liebenberg W, de Villiers MM, Wurster DE, Swanepoel E, Dekker TG. The effect of polymorphism on powder compaction and dissolution properties of chemically equivalent oxytetracycline hydrochloride powders. Drug Dev Ind Pharm. 1999;25:1027-33.
83. Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Bioavail. 2010;2(2):28-36.
84. Sharma D, Soni M, Kumar S, Gupta GD. Solubility enhancement-eminent role in poorly soluble drugs. Res J Pharm Technol. 2009;2(2):220-4.
85. Stephenson GA, Aburub A, Woods TA. Physical stability of salts of weak bases in the solid-state. J Pharm Sci. 2011;100:1607-17.
86. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617-30.
87. Burton WK, Cabrera N, Frank FC. The growth of crystals. Philos Trans R Soc. 1951;243:299-358.
88. Human HJ, van der Eerden JP, Jetten LAMJ, Oderkerken JGM. On the surface roughening transition of faceted to non faceted growth of diphenyl for different organic solvents and the melt. J Cryst Growth. 1981;51:598-600.
89. Addadi L, Berkovitch-Yellin Z, Weissbuch I, Lahav M, Leiserwitz L. A link between macroscopic phenomena and molecular chirality crystals as probes for the direct assignment of absolute configuration for chiral molecules. Top. Stereochem. 1986;16:2-83.
90. Adhiyaman R, Basu SK. Crystal modification of dipyridamole using different solvents and crystallisation conditions. Int J Pharm. 2006;321:27-34.
91. Nokhodchi A, Bolourtchian N, Dinarvand R. Crystal modification of phenytoin using different solvents and crystallisation conditions. Int J Pharm. 2003;250:85-97.
92. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56:335-47.
93. Kobayashi Y, Ito S, Itai S, Yamamoto K. Physicochemical properties and bioavailability of arbamazepine polymorphs and dehydrate. Int J Pharm. 2000;193:137-46.
94. Tian F, Sandler N, Aaltonen J, Lang C, Saville DJ, Gordon KC, Strachan CJ, Rantanen J, Rades T. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J Pharm Sci. 2007;96:584-94.
95. Badawy SI, Hussain MA. Microenvironmental pH modulation in solid dosage forms. J Pharm Sci. 2007;96:948-59.
96. Tatavarti AS, Hoag SW. Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices. J Pharm Sci. 2006;95:1459-68.
97. Badawy SI, Gray DB, Zhao F, Sun D, Schuster AE, Hussain MA. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res. 2006;23:989-96.
98. Brandl M, Magill A, Rudraraju V, Gordon MS. Approaches for improving the stability of ketorolac in powder blends. J Pharm Sci. 1995;84:1151-3.
99. Chen JG, Markovitz DA, Yang AY, Rabel SR, Pang J, Dolinsky O, Wu LS, Alasandro M. Degradation of a fluoropyridinyl drug in capsule formulation: degradant identification, proposed degradation mechanism, and formulation optimization. Pharm Dev Technol. 2000;5:561-570.
100. Glombitza BW, Schmidt PC. Surface acidity of solid pharmaceutical excipients. Part 2. Effect of the surface acidity on the decomposition rate of acetylsalicylic acid. Eur J Pharm Biopharm. 1995;41:114-9.
101. Strickley RG, Viso GC, Lin LH, Gu L. An unexpected pH effect of moexipril lyophilized powder. Pharm Res. 1989;6:971-5.
102. Song Y, Schowen RL, Borchardt RT, Topp EM. Effect of pH on the rate of asparagines deamidation in polymeric formulations: pH-rate profile. J Pharm Sci. 2001;90:141-56.
103. Mohanachandran PS, Sindhumol PG, Kiran TS. Enhancement of solubility and dissolution rate: an overview. Int J Compr Pharm. Issue 0976-8157.
104. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm. 2002;54:107-117.
105. Perissutti B, Rubessa F, Mariarosa M, Voinovich D. Formulation design of carbamazepine fastrelease tablets prepared by melt granulation technique. Int J Pharm. 2003;256:53-63.
106. Yang D, Kulkarni R, Behme RJ, Kotiyan PN. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. Int J Pharm. 2007;329:72-80.
107. Mitchell SA, Reynolds TD, Dasbach TP. A compaction process to enhance dissolution of poorly water-soluble drugs using hydrxypropyl methylcellulose. Int J Pharm. 2003;250:3-11.
108. Patil SK, Kalpesh S, Parik WVB, Akarte AM, Baviskar DT. Strategies for solubility enhancement of poorly soluble drugs. Int J Pharm Sci Rev Res. 2011;8(2):74-80.
109. Pant P, Bansal K, Rao PRT, Padhee K, Sathapathy A, Kochhar PS. Micronization: an efficient tool for dissolution enhancement of dienogest. Int J Drug Dev Res. 2011;3(2):329-33.
110. Gupta AK, Sehrawat SK. Bioavailability enhancement of poorly water soluble drugs: A review. Int. J. of Pharm. & Life Sci. (IJPLS) 2011;2(3):640-50.
111. Yaeger S, Advances in powder micronization technology for the pharmaceutical industry. The J Pharm. Processing [cited from http://hmicronpowder.com/ADVANCES_PHARMA.PDF on 2012, Feb.12].
112. Kumar A, Sahoo SK, Padhee K, Kochar PS, Satapathy A, Pathak N. Review on solubility enhancement techniques for hydrophobic drugs. Pharmacie Globale IJCP. 2011;2:1-7.
113. Chaumeil JC. Micronization: A method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol. 1998;20(3):211.
114. Steckel H, Thies J, Muller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm 1997152:99-110.
115. Reverchon E, Porta GD, Spada A, Antonacci. A Griseofulvin micronization and dissolution rate improvement by supercritical assisted atomization. J Pharm Pharmacol. 2004;56(11):1379-87.
116. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930-4.
117. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46:75-87.
118. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160:229-37.
119. Li XS, Wang JX, Shen ZG, Zhang PY, Chen JF, Yun J. Preparation of uniform prednisolone mi crocrystals by a controlled microprecipitation method. Int J Pharm. 2007;342:26-32.
120. Eerdenbrugh VB. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64-75.
121. Lindfors L, Forssen S, Westergren J, Olsson U. Nucleation and crystal growth in supersaturated solutions of a model drug. J Colloid Interface Sci. 2008;325:404-13.
122. Chen HB. A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid-base neutralization reactions. Nanotechnology. 2008;19:375104.
123. Xia D, Quan P, Piao H, Piao H, Suna S, Yin Y, Cui F. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40:325-34.
124. Ruecroft G, Hipkiss D, Ly T, Maxted N, Cains PW. Sonocrystallization: the use of ultrasound for improved industrial crystallization, Org Process Res Dev. 2005;9:923-32.
125. Luque de Castro MD, Priego-Capote F. Ultrasound-assisted crystallization (sonocrystallization). Ultrason Sonochem. 2007;14:717-24.
126. Kim YH, Lee K, Koo KK, Shul YG, Haam S. Comparison study of mixing effect on batch cooling crystallization of 3-nitro-1,2,4-triazol-5-one (NTO) using mechanical stirrer and ultrasound irradiation, Cryst Res Technol. 2002;37:928-44.
127. Dalvi SV, Dave RN. Controlling particle size of a poorly water-soluble drug using ultrasound and stabilizers in antisolvent precipitation, Ind Eng Chem Res. 2009;48:7581-93.
128. Yeo SD, Lee JC. Crystallization of sulfamethizole using the supercritical and liquid antisolvent processes, J Supercrit Fluids 2004;30:315-23.
129. Guo Z, Zhang M, Li H, Wang J, Kougoulos E. Effect of ultrasound on anti-solvent crystallization process, J Cryst Growth 2005;273:555-63.
130. Siddiqui SW, Zhao Y, Kukukova A, Kresta SM. Characteristics of a confined impinging jet reactor: energy dissipation, homogeneous and heterogeneous reaction products, and effect of unequal flow. Ind Eng Chem Res. 2009;48:7945-58.
131. Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129-39.
132. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59:419-26.
133. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-44.
134. Sylvestre JP, Tang MC, Furtos A, Leclair G, Meunier M, Leroux JC. Nanonization of megestrol acetate by laser fragmentation in aqueous milieu. J Control Release 2011;149:273-80.
135. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91-9.
136. Block LH. Emulsions and microemulsions. In: Lieberman HA, Rieger MM, Banker GS editors. Pharmaceutical dosage forms-disperse systems, Vol. 2. New York: Marcel Dekker; 1989. p. 335-78.
137. Klang S, Benita S. Design and evaluation of submicron emulsions as colloidal drug carriers for intravenous administration. In: Benita S, editor. Submicron emulsions in drug targeting and delivery, Drug targeting and delivery, Vol. 9. Amsterdam: Harwood Academic; 1998. p. 119-52.
138. Jumaa M, Muller BW. The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int J Pharm. 1998;163:81-9.
139. D. Rousseau. Fat crystals and emulsion stability-a review. Food Res Int. 2000;33:3-14.
140. Schmitt J. Parenterale Fettemulsionen als Arzneistofftrager. In: Müller RH and Hildebrand G, editors. Pharmazeutische technologie: Moderne arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1998. p. 137-42.
141. Collins-Gold LC, Lyons RT, Bartholow LC. Parenteral emulsions for drug delivery. Adv Drug Delivery Rev. 1990;5:189-208.
142. Mou D. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs. Int J Pharm. 2008;353:270-6.
143. Jahn A. Preparation of nanoparticles by continuous-flowmicrofluidics. J Nanopart Res. 2008;10: 925-34.
144. Ganta S. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol. 2008;4:165-73.
145. Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm. 2008;347:136-43.
146. Tagne JB. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm. 2008;5:1055-63.
147. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6:928-39.
148. Silva APC. Development of topical nanoemulsions containing the isoflavone genistein. Pharmazie. 2009;64:32-5.
149. Shakeel F. Celecoxib nanoemulsion for transdermal drug delivery: characterization and in vitro evaluation. J Disp Sci Technol. 2009;30:834-42.
150. Jones M, Leroux J. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101-11.
151. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137-72.
152. Sutton D, Nasonglka N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24:1029-46.
153. Gaucher G, Defresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109:169-88.
154. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release. 2008;126:122-9.
155. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water soluble drugs. Drug Discovery Today. 2011;16(78):354-60.
156. Nakanishi, T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J Control Release. 2001;74:295-302.
157. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191-202.
158. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelleencapsulated doxorubicin. Br J Cancer 2004;91:1775-81.
159. Vasconcelos T, Samento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today. 2007;12:1068-75.
160. Karavas E, Ktistis G, Xenakis A, Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm. 2006;63:103-14.
161. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. Use of compressed gas precipitation to enhance the dissolution omogeni of a poorly water-soluble drug: generation of drug microparticles and drug-polymer solid dispersions. Int J Pharm. 2006;308:69-83.
162. Chaudhari P. Current trends in solid dispersions techniques. Pharminfo.net [INTERNET]. 2006 May 17;4(3): [about 11 screens]. Available from: http://www.pharmainfo.net/reviews/current-trends-solid-techniques [Last cited on 2012 Feb 6].
163. Pokharkar VB, Mandpe LP, Padanwar MN, Ambike AA, Mahadik KR, Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006;167:20-5.
164. Vilhelmsen T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm. 2005;303:132-42.
165. Pokharkar VB. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006;167:20-5.
166. Won DH. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm. 2005;301:199-208.
167. Van den Mooter G. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm. 2006;316:1-6.
168. Dua K, Pabreja K, Ramana MV. Preparation, characterization and in vitro evaluation of aceclofenac solid dispersions, ARS Pharmaceutica. 2010;51(1):57-76.
169. Gahoi S, Jain GK, Singhal M, Anwar M, Ahmad FJ, Khar RK. Influence of novel dispersed fusion technique on dissolution and pharmacotechnical properties of pharmaceutical solid dispersion. Int J Pharm Sci Rev Res. 2011;8(2):170-5.
170. Xie Y, Li G, Yuan X, Cai Z, Rong R. Preparation and in vitro evaluation of solid dispersions of total flavones of hippophae Rhamnoides L. AAPS PharmSciTech. 2009;10(2):631-40.
171. Manimaran V, Damodharan N, Mothilal M, Rajkumar K, Chalackal RM. Enhancement of dissolution rate of glibenclamide by solid dispersion technology. Int J Curr Pharm Res. 2010;2(3): 14-7.
172. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm. 2005;59:119-26.
173. Chauhan B, Shimpi S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS PharmSciTech. 2005;6: E405-12.
174. Al-Obaidi H, Brocchini S, Buckton G. Anomalous properties of spray dried solid dispersions. J Pharm Sci. 2009;98:4724-37.
175. Dhirendra K, Lewis S, Udupa N, Atin K. Solid dispersion: a review. Pak J Pharm Sci. 2009;22: 234-46.
176. Singh SK, Srinivasan KK, Gowthamarajan K, Prakash D, Gaikwad NB. Investigation of preparation parameters of solid dispersion and lyophilization technique in order to enhance the dissolution of poorly soluble glyburide. J Pharm Res. 2011;4:2718-23.
177. Lokamatha KM, Shanta Kumar SM, Rama Rao N. Enhancement of solubility and dissolution rate of nevirapine by solid dispersion technique using dextran: preparation and in vitro evaluation. Int J Pharm Res Dev. 2011;2:1-8.
178. Nitika A, Kamal K, Arun G, Suresh P. Solid dispersions -preparation methods, pharmaceutical applications and evaluation techniques: a review. Novel Science. Int J Pharm Sci. 2012;1(2):103-14.
179. Karanth H, Shenoy VS, Murthy RR. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS PharmSciTech 2006;7:E31-8.
180. Fages J, Lochard H, Letourneau JJ, Sauceau M, Rodier E. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol. 2004;141:219-26.
181. Sethuraman S, Arunachalam A, Karthikeyan M, Konam K, Prasad PH, Senthilraj R. Formation and Characterization of solid dispersion of Piroxicam. Int J Preclin Pharm Res. 2011;2:1-6.
182. Liu H, Zhou LL, Wei LL, Guo H, Nie SF, Yang XG, Tang R, Pan WS. Preparation of budesonidepoly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm. 2007;33:959-66.
183. Wakerly MG, Pouton CW, Meakin BJ, Morton FS. Self emulsification of vegetable oil-non-ionic surfactant mixtures. ACS Symp Series. 1986;311:242-55.
184. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50:179-88.
185. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12:1561-72.
186. Craig DQM. The use of self-emulsifying systems as a means of improving drug delivery. B T Gattefosse 1993;86:21-31.
187. Reiss H. Entropy-induced dispersion of bulk liquids. J Colloids Interface Sci. 1975;53:61-70.
188. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine and Pharmacotherapy. 2004;58:173-82.
189. Dabros T, Yeung A, Masliyah J, Czarnecki J. Emulsification through area contraction. J Colloids Interface Sci. 1999;210:222-4.
190. Groves MJ, Mustafa RMA, Carless JE. Phase studies of mixed phosphate surfactants, n-hexane and water. J Pharm Pharmacol. 1974;26:616-23.
191. Pouton CW, Wakerly MG, Meakin BJ. Selfemulsifying systems for oral delivery of drugs, Proc. Int. Symp. Control Release Bioact Mater. 1987;14:113-4.
192. Craig DQM. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995;114:103-10.
193. Craig DQM, Lievens HSR, Pitt KG, Storey DE. An investigation into the physicochemical properties of self-emulsifying systems using low frequency dielectric spectroscopy, surface tension measurements and particle size analysis. Int J Pharm. 1993;96:147-55.
194. Patel PA, Chaulang GM, Akolkotkar A, Mutha SS, Hardikar SR, Bhosale AV. Self emulsifying drug delivery system: a review. Res J Pharm and Tech. 2008;1(4):313-23.
195. Brewster M.E, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59:645-66.
196. Milecki J, Fales H, Pannell L, Uekama K. Hydroxypropyl- β -cyclodextrin in preparation and characterization: effects on solubility of drugs. Int J Pharm. 1986;29:73-82.
197. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1-11.
198. Fromming KH, Szejtli J. Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic; 1994.
199. Pitha J, Milecki J, Fales H, Pannell L, Uekama K. Hydroxypropyl- β-cyclodextrin in preparation and characterization: effects on solubility of drugs. Int J Pharm. 1986;29:73-82.
200. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins-drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-25.
201. H. Preparation, structure, property and application of branched cyclodextrins. In: Duchene D, editor. Newtrends in cyclodextrins derivatives.: Editions de Sante;1991. p.97-156.
202. Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005a;302:18-28.
203. Li P, Tabibi E, Yalkowsky SH. Combined effect of complexation and pH on solubilization. J Pharm Sci. 1998;87:1535-7.
204. Sigurosson HH, Masson M, Schipper N. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie. 2004c;59:25-9.
205. Loftsson T, Yamakawa T, Nishimura S. Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin. J Control Rel. 2003;86:101-13.
206. Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci. 1999;88:1107-11.
207. Furuta T, Yoshii H. Miyamoto A, Yasunishi A, Hirano H. Effects of water of inclusion complexes of d-limonene and cyclodextrins. Supramol Chem. 1993;1:321-5.
208. Choudhury S, Nelson KF. Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-b-cyclodextrin. Int J Pharm. 1992;85:175-80.
209. Stracciari GL, Malvisi J, Anfossi P, Fregnan GB. Pharmacokinetics of dipyridamole-β-cyclodextrin complex in dogs. Arch Int Pharmacodyn Ther. 1989;300:7-13.
210. Vila-Jato JL, Blanco J, Vilar A. Spironolactone/β-cyclodextrin complex: oral bioavailability in humans, Pharm Technol. 1986;32(2):82-5.
211. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system, Adv Drug Deliv Rev. 1999;36:125-41.
212. Hirayama F, Horikawa T, Yamanaka M, Uekama K. Enhanced bioavailability and reduced metabolism of salbutamol by perbutanoyl-b-cyclodextrin after oral administration in dogs. Pharm Sci. 1995;1:517-20.
213. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull. (Tokyo). 2004;52:900-15.
214. Yunomae K, Arima H, Hirayama F, Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 2003;536:225-31.
215. Frijlink HW, Schoonen AJM, Lerk CF. The effects of cyclodextrins on drug absorption. I. In vitro observations. Int J Pharm. 1989;49:91-102.
216. Bekers O, Uijtendaal EV, Beijnen JH, Buit A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991;17:1503-49.
217. Barenholz Y, Crommelin DJ. Liposomes as pharmaceutical dosage forms. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology, Vol. 9. New York: Marcel Dekker; 1994. p. 1-39.
218. Schubert R. Liposomen in arzneimitteln. In: Muller RH, Hildebrand GE, editors. Pharmazeutische technologie: Moderne arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1998. p. 219-42.
219. Martin FJ. Pharmaceutical manufacturing of liposomes. In: Tyle P, editor. Specialized drug delivery systems. Vol. 41. Drugs and the pharmaceutical sciences. New York: Marcel Dekker; 1990. p. 267-316.
220. Doktorovová, S., Morsy, T., Balcão, V.M., Souto, E.B., The role of lipids in drug absorption through GIT. J Fac Hlth Sci. 2008;5:192-8. (UFP ISSN: 1646-0480).
221. Waterhouse DN, Madden TD, Cullis PR. Preparation, characterization, and biological analysis of liposomal formulations of Vincristine. Methods Enzymol. 2005;391:40-57.
222. Florence AT, Cable C. Non-ionic surfactant vesicles (niosomes) as vehicles for doxorubicin delivery. In: Gregoriadis G, Florence AT, Patel HM, editors. Liposomes in drug delivery. Chur, Switzerland: Harwood Academic; 1993. p. 239-53.
223. Iwanaga K, Ono S, Narioka K, Morimoto K, Kakemi M, Yamashita S, Nango N, Oku N. Oral delivery of insulin by using surface coating liposomes Improvement of stability of insulin in GI tract. Int J Pharm. 1997;157:73-80.
224. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Biopharm. 2000;50:161-77.
225. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechol. 2004;113:151-70.
226. Muchow M, Maincent P, Muller RH. Lipid Nanoparticles with a Solid Matrix (SLN, NLC, LDC) for Oral Drug Delivery. Drug Dev Ind Pharm. 2008;34:1394-405.
227. Rodriguez-Hornedo N. Crystallization and the properties of crystals. In: J.Swarbrick and J. C. Boylan editors. Encyclopedia of pharmaceutical technology, Vol. 3. New York: Marcel Dekker; 1990. p. 399-434.
228. Liedtke S, Wissing S, Muller RH, Mader K. Influence of high pressure omogenization equipment on nanodispersions characteristics. Int J Pharm. 2000;196:183-5.
229. Gasco MR. Method for producing solid lipid microspeheres having a narrow size distribution, United States Patent. 1993;5:250,236.
230. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Biopharm. 1996;43:104-9.
231. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification- diffusion technique. Int J Pharm. 2003;257:153-60.
232. Yuan FQ HH, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm. 2002;239:121-8.
233. Speiser P. Lipid nanopellets als Trager system für Arzneimittel zur peroralen Anwendung, European Patent EP 0167825, 1990.
234. Domb AJ. Lipospheres for controlled delivery of substances, United States Patent Bibliography. 1993;5:188,837.
235. Mehnert W, Maderk K. Solid lipid nanoparticles. Production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-96.
236. Muller RH, Maaben S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407. J Drug Target 1996;4:161-70.
237. Garcia-Fuentes M, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf., B. 2003;27:159-68.
238. Demirel M, Yazan Y, Muller RH, Kilic F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul. 2001;8:359-371.
239. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 2006;114:53-9.
240. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size cell line and cell density. J Control Release 2001;1:39-51.
241. How CW, Abdullah R, Abbasalipourkabir R. Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with polysorbate 20 and polysorbate 80. African J Biotechnol. 2011;10(9):1684-9.
242. Radtke M, Muller RH. Nanostructured lipid drug carriers. New Drugs. 2001;2:48-52.
243. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121-8.
244. Souto EB, Muller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot highpressure homogenization. J Microencapsul. 2006;23: 377-88.
245. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62-76.
246. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74(3):474-82.
247. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, Pan YS, Tang X. Preparation and characterization of vinpocetine-loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1-2):179-85.
248. Dohrn R, Bertakis E, Behrend O, Voutsas E, Tassios D. Melting point depression by using supercritical CO2 for a novel melt dispersion micronization process. J Mole Liq. 2007;131-2.
249. Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovier. AAPS PharmSciTech 2003;4:E45.
250. Rodier E, Lochard H, Sauceau M, Letourneau J-J, Freiss B, Frages J. A three-step supercritical process to improve the dissolution rate of Eflucimibe. Eur J Pharm Sci. 2005;26:184-93.
251. Al-Marzouqui AH, Jobe B, Dowaidar AF, Maestrelli F, Mura P. Evaluation of supercritical fluid technology as preparative technique of benzocainecyclodextrin complexes-comparison with conventional methods. J Pharm Biomed Anal. 2007;43:566-74.
252. Vamsi KM, Gowrisankar D. Role of Supercritical fluids in the Pharmaceutical Research-A Review. Indian J Pharm Edu. 2007;41(1):10-7.